Home・Stock List・Novocure Ltd

Novocure Ltd

Closed

SectorHealthcare

17.79 -10.6

Buy Sell

Overview

Share price change

24h

Current

Min

17.23

Max

21.33

Key metrics
By Trading Economics
Income	-47M -71M
Sales	-295K 174M
EPS	-0.62
Profit margin	-40.871
Employees	1,605
EBITDA	-29M -63M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+27.56% upside

Market Stats
By TradingEconomics
Market Cap	401M 1.8B
Previous open	28.39
Previous close	17.79

News Sentiment

By Acuity

55%

45%

273 / 340 Healthcare

Novocure Ltd Chart

Past performance is not a reliable indicator of future results.

Related News

24 Jul 2026, 19:41 UTC

News

Social Media

Novocure Ltd's stock is lower following its Q2 earnings report, despite a narrower loss and revenue beat. Analysts lowered price targets amid ongoing investor concerns.

22 Jul 2026, 20:04 UTC

Shares of Novocure Ltd. are lower today, continuing a decline since Tuesday's close amid broader market uncertainty ahead of the Federal Reserve meeting.

20 Jul 2026, 14:36 UTC

Novocure Ltd. is trading higher since Friday's close, despite pulling back from an early session high amid broader market volatility from geopolitical tensions.

Peer Comparison

Price change

Novocure Ltd Forecast

Price Target

By TipRanks

27.56% upside

12 Months Forecast

Average 25.5 USD 27.56%

High 52 USD

Low 17 USD

Based on 6 Wall Street analysts offering 12 month price targets forNovocure Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Novocure Ltd - Dist in the past 3 months.

Sentiment

By Acuity

273 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.